Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.